Skip to main content

REVIEW article

Front. Cardiovasc. Med.
Sec. Cardiovascular Metabolism
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1445739
This article is part of the Research Topic Obesity and Cardiovascular Disease View all 3 articles

Protein Tyrosine Phosphatase 1B in Metabolic and Cardiovascular Diseases: From Mechanisms to Therapeutics

Provisionally accepted
Yan Sun Yan Sun Frank Dinenno Frank Dinenno Peiyang Tang Peiyang Tang Maria Kontaridis Maria Kontaridis *
  • Masonic Medical Research Institute (MMRI), Utica, United States

The final, formatted version of the article will be published soon.

    Protein Tyrosine Phosphatase 1B (PTP1B) has emerged as a significant regulator of metabolic and cardiovascular disease. It is a non-transmembrane protein tyrosine phosphatase that negatively regulates multiple signaling pathways integral to the regulation of growth, survival, and differentiation of cells, including leptin and insulin signaling, which are critical for development of obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Given PTP1B's central role in glucose homeostasis, energy balance, and vascular function, targeted inhibition of PTP1B represents a promising strategy for treating these diseases. However, challenges, such as off-target effects, necessitate a focus on tissue-specific approaches, to maximize therapeutic benefits while minimizing adverse outcomes. In this review, we discuss molecular mechanisms by which PTP1B influences metabolic and cardiovascular functions, summarize the latest research on tissue-specific roles of PTP1B, and discuss the potential for PTP1B inhibitors as future therapeutic agents.

    Keywords: protein tyrosine phosphatase, PTP1B, cardiovascular disease, Insulin Resistance, diabetes, Obesity, Therapeutics

    Received: 11 Jun 2024; Accepted: 05 Aug 2024.

    Copyright: © 2024 Sun, Dinenno, Tang and Kontaridis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Maria Kontaridis, Masonic Medical Research Institute (MMRI), Utica, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.